BDA
16.3.2022 20:53:09 CET | Business Wire | Press release
The sold-out Bermuda Business Development Agency’s (BDA) Bermuda Risk Summit was declared an immense success, with over 80 overseas delegates in attendance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220316005995/en/
The immediate economic impact of the event, which had a total of 350 delegates, including lodging, transportation, food and beverage, retail and recreation was estimated at over one million dollars, and supported around 200 jobs. Based on market feedback, dozens of additional visitors flew to Bermuda for business meetings around the event, bringing additional economic impacts to the island.
The Hon. Jason Hayward, JP, MP, Minister of Economy and Labour, who attended the event, said, “Congratulations to the BDA for organising such a successful inaugural event which had a positive impact on Bermuda’s economy and community. Bermuda remains the world’s risk capital, and for decades, Bermuda based insurers have been leaders in the global reinsurance industry. It was a pleasure to meet and hear first-hand updates from some of the world’s foremost risk and regulatory experts. The Government along with the Bermuda Monetary Authority (BMA) plays a critical role in the success of Bermuda’s Insurance Industry and remains a partner, committed to supporting the growth of the industry.”
David Hart, BDA CEO, said, “We received fantastic feedback for taking a leadership role in organising the first in-person risk event since 2019. A running theme across the event was how great it was to get off zoom and see each other again in person after such a long absence. Our hope was always that this event would provide an opportunity for Bermuda’s risk industry to start charting a way forward together and meet prior to mid-year renewal season. We look forward to building on this success by making our second annual event on March 6-8, 2023, even bigger and better next year.”
The Risk Summit was kicked off by a ‘sea-side’ chat between Bermuda’s Premier, The Hon. David Burt, JP, MP, and Mr. Hart. In his remarks, Premier Burt said, “Thank you to all those who are visiting but thank you also to our risk industry who throughout this pandemic has been a bedrock of support inside of the community...The objective of this government as we move beyond the pandemic is to make sure that Bermuda maintains its leadership across the board and remains the most competitive place to deploy capital.”
The seaside chat was followed by a panel made up of global CEOs, including Albert Benchimol, President & CEO, Axis; Stephen Catlin, Chairman & CEO, Convex; Marc Grandisson, CEO, Arch Capital Group; Chris Schaper, CEO, AIG Re; and Megan Thomas, CEO, Hamilton Re. In his remarks, CEO panel moderator John Huff, CEO, of the Association of Bermuda Insurers and Reinsurers (ABIR) welcomed the three ABIR-sponsored Bermuda College students in the audience. Also in the audience was a contingent of risk and insurance students from Eastern Kentucky University who flew down especially for the event and to learn about Bermuda’s globally important risk industry.
Day two started off with breakfast keynote on terrorism risk from Julian Enoizi, CEO Pool Re, and was followed by panels featuring rating agencies, brokers, life, and a Florida Legislative Update. Day two was rounded off by an incredible keynote lunch featuring Aon President, Eric Andersen.
Our final day began with a keynote on Florida risk by Joseph Petrelli, President, Demotech, with panels on captives, cyber, InsurTech, and Insurance Linked Securities (ILS) following. Day 3 was closed out by remarks about an upcoming Bermuda ESG benchmarking survey by Miqdaad Versi, Head of ESG, Oxbow Partners, UK.
The BDA thanks our diamond sponsors, ABIR, Aon and EY, our gold sponsor Appleby, and our silver sponsors Ariel Re, Kirkland & Ellis, KPMG, and SiriusPoint. We were also fortunate to have Bermuda Brokers, Florida Insurance Council, Kettle, Meenan P.A., and Goslings as additional event sponsors. Our media partner was The Insurer. The Bermuda Risk Summit was a SafeKey event.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, relocate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005995/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom